Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Neuroendocrine × Irinotecan × Clear all

Phase

Status

Completed 2 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 53 Colonic Neoplasms 23 Rectal Neoplasms 21 Neoplasms 18 Pancreatic Neoplasms 17 Neoplasm Metastasis 14 Stomach Neoplasms 8 Esophageal Neoplasms 8 Carcinoma, Non-Small-Cell Lung 6 Small Cell Lung Carcinoma 5 Sarcoma 5 Glioma 5 Glioblastoma 5 Brain Neoplasms 5 Neuroblastoma 4 Lung Neoplasms 4 Gliosarcoma 4 Intestinal Neoplasms 3 Gastrointestinal Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Carcinoma, Renal Cell 3 Adenocarcinoma 3 Sarcoma, Ewing 2 Recurrence 2 Rectal Diseases 2 Oligodendroglioma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neoplasms by Site 2 Intestinal Diseases 2 Gastrointestinal Diseases 2

Interventions

iadademstat 1 Temozolomide 1 Sunitinib 1 Paclitaxel 1 Irinotecan 1 Fluorouracil 1 Everolimus 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡